HAYWARD, Calif., Jan. 22 /PRNewswire/ -- Arete Therapeutics Inc., a privately-held biopharmaceutical company developing first-in-class small molecule therapeutics for the treatment of cardiovascular, inflammatory and metabolic diseases, today announced the addition of James A. Bristol, Ph.D. as a scientific and strategic advisor, to continue to enhance the efficiency and efficacy of the company's clinical, preclinical, and discovery programs.
"Jim brings over 30 years of exceptional pharmaceutical drug discovery and development experience, which we believe will be instrumental in determining the most advantageous market opportunities for our products, balancing our portfolio of compounds, and optimizing our overall discovery strategy," said Dinesh V. Patel, Ph.D., president and chief executive officer of Arete Therapeutics Inc.
James A. Bristol, Ph.D. comes to Arete Therapeutics after his retirement from Pfizer, where he was most recently senior vice president of worldwide drug discovery research. During the three and a half years Jim led Pfizer's worldwide discovery research, the organization produced approximately 45 drug candidates in 11 therapeutic areas each year. Prior to Pfizer, Dr. Bristol held positions of increasing responsibility within the scientific management team at both Parke-Davis and Schering Plough Corporation. He is chairman of the Board of Managers of Deciphera Pharmaceuticals, an executive in residence at Oxford Bioscience Partners, and a consultant to MPM Capital. Dr. Bristol is the author of over 100 publications, abstracts, and patents. He received his Ph.D. in organic chemistry from the University of New Hampshire and his B.S. in chemistry from Bates College.
"Arete Therapeutics is unique in its approach to cardiovascular drug discovery, with the efficiency of a large pharmaceutical company and the innovation of cutting-edge biotechnology," said James A. Bristol, Ph.D., scientific and strategic advisor to Arete Therapeutics Inc. "I look forward to finding the ideal balance of the sophisticated business acumen of the management team with the strong science of the soluble epoxide hydrolase pathway to successfully guide Arete's development and discovery programs into the future."
About Arete Therapeutics Inc.
Arete Therapeutics Inc. is a privately held pharmaceutical Company discovering and developing first-in-class small molecule drugs directed at soluble epoxide hydrolase (s-EH), a novel target for cardiovascular, metabolic and inflammatory diseases. By targeting s-EH which plays a key role in the arachidonic acid pathway, the Company is addressing the very large market need for a unique anti-hypertensive drug with renal sparing, cardio-protective and anti-inflammatory properties. Arete has discovered and developed a series of proprietary and chemically diverse molecules with preclinical efficacy in various animal models of hypertension, metabolic syndrome, and inflammation, and is conducting a phase 1 clinical trial with its first-in-class antihypertensive drug AR9281. The Company has raised a total of $51 million in Series A financing led by Frazier Healthcare Ventures (http://www.frazierhealthcare.com), Alta Partners (http://www.altapartners.com), Three Arch Partners (http://www.threearchpartners.com), Burrill & Company (http://www.burrillandco.com) and Altitude Life Science Ventures (http://www.altitudefunds.com). For more information on Arete Therapeutics, please visit http://www.aretetherapeutics.com.
CONTACT: Angela Bitting, +1-925-202-6211, email@example.com, for Arete
Web site: http://www.aretetherapeutics.com/